Immunohistochemical Analysis of LRIG Proteins in Meningiomas: Correlation Between Estrogen Receptor Status and LRIG Expression

Overview

Journal J Neurooncol

Publisher Springer

Date 2012 Apr 10

PMID 22484910

Citations 9

Authors

Soma Ghasimi

Hannu Haapasalo

Mine Eray

Katariina Korhonen

Thomas Brannstrom

Hakan Hedman

Ulrika Andersson

Affiliations

Soon will be listed here.

Abstract

The leucine-rich repeats and immunoglobulin-like domains (LRIG) protein family is comprised of three integral membrane proteins: LRIG1, LRIG2, and LRIG3. LRIG1 is a negative regulator of growth factor signaling. The expression and subcellular localization of LRIG proteins have prognostic implications in primary brain tumors, such as oligodendrogliomas and astrocytomas. The expression of LRIG proteins has not previously been studied in meningiomas. In this study, the expression of LRIG1, LRIG2, and LRIG3 was analyzed in 409 meningiomas by immunohistochemistry, and potential associations between LRIG protein expression and tumor grade, gender, progesterone receptor status, and estrogen receptor (ER) status were investigated. The LRIG proteins were most often expressed in the cytoplasm, though LRIG1 also showed prominent nuclear expression. Cytoplasmic expression of LRIG1 and LRIG2 correlated with histological subtypes of meningiomas (p = 0.038 and 0.013, respectively). Nuclear and cytoplasmic expression of LRIG1 was correlated with ER status (p = 0.003 and 0.004, respectively), as was cytoplasmic expression of LRIG2 (p = 0.006). This study is the first to examine the expression of LRIG proteins in meningiomas, and it shows a correlation between ER status and the expression of LRIG1 and LRIG2, which suggests a possible role for LRIG proteins in meningioma pathogenesis.

Citing Articles

LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor.

Ji Y, Kumar R, Gokhale A, Chao H, Rycaj K, Chen X Semin Cancer Biol. 2021; 82:120-133.

PMID: 33476721 PMC: 8286266. DOI: 10.1016/j.semcancer.2020.12.016.

Recurrence/Regrowth in Grade I Meningioma: How to Predict?.

de Carvalho G, da Silva-Martins W, de Magalhaes K, Nunes C, Soares A, de Assis Tafuri L Front Oncol. 2020; 10:1144.

PMID: 32903787 PMC: 7438949. DOI: 10.3389/fonc.2020.01144.

Expression of LRIG1 is Associated With Good Prognosis for Human Non-small Cell Lung Cancer.

An Y, Zhao Z, Ou P, Wang G Medicine (Baltimore). 2015; 94(47):e2081.

PMID: 26632716 PMC: 5058985. DOI: 10.1097/MD.0000000000002081.

Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.

Morrison M, Williams M, Vaught D, Hicks D, Lim J, McKernan C Oncogene. 2015; 35(9):1143-52.

PMID: 26148232 PMC: 4703573. DOI: 10.1038/onc.2015.169.

LRIG and cancer prognosis.

Lindquist D, Kvarnbrink S, Henriksson R, Hedman H Acta Oncol. 2014; 53(9):1135-42.

PMID: 25180912 PMC: 4438349. DOI: 10.3109/0284186X.2014.953258.

References

Umansky F, Shoshan Y, Rosenthal G, Fraifeld S, Spektor S . Radiation-induced meningioma. Neurosurg Focus. 2008; 24(5):E7. DOI: 10.3171/FOC/2008/24/5/E7. View

Hedman H, Lindstrom A, Tot T, Stendahl U, Henriksson R, Hellberg D . LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix. Acta Oncol. 2010; 49(6):812-5. DOI: 10.3109/0284186X.2010.492789. View

Yi W, Holmlund C, Nilsson J, Inui S, Lei T, Itami S . Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1. Exp Cell Res. 2010; 317(4):504-12. DOI: 10.1016/j.yexcr.2010.11.005. View

Nilsson J, Vallbo C, Guo D, Golovleva I, Hallberg B, Henriksson R . Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun. 2001; 284(5):1155-61. DOI: 10.1006/bbrc.2001.5092. View

Lindstrom A, Ekman K, Stendahl U, Tot T, Henriksson R, Hedman H . LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer. 2007; 18(2):312-7. DOI: 10.1111/j.1525-1438.2007.01021.x. View

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S . Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7):844-7. DOI: 10.1038/nm0798-844. View

Pravdenkova S, Al-Mefty O, Sawyer J, Husain M . Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J Neurosurg. 2007; 105(2):163-73. DOI: 10.3171/jns.2006.105.2.163. View

Patil C, Veeravagu A, Lad S, Boakye M . Craniotomy for resection of meningioma in the elderly: a multicentre, prospective analysis from the National Surgical Quality Improvement Program. J Neurol Neurosurg Psychiatry. 2009; 81(5):502-5. DOI: 10.1136/jnnp.2009.185074. View

Guo D, Nilsson J, Haapasalo H, Raheem O, Bergenheim T, Hedman H . Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol. 2006; 111(3):238-46. DOI: 10.1007/s00401-006-0032-5. View

10.

Andersson U, Guo D, Malmer B, Bergenheim A, Brannstrom T, Hedman H . Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol. 2004; 108(2):135-42. DOI: 10.1007/s00401-004-0875-6. View

11.

Tanemura A, Nagasawa T, Inui S, Itami S . LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg. 2005; 31(4):423-30. DOI: 10.1111/j.1524-4725.2005.31108. View

12.

Korhonen K, Raitanen J, Isola J, Haapasalo H, Salminen T, Auvinen A . Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland. Cancer Causes Control. 2010; 21(12):2149-56. DOI: 10.1007/s10552-010-9634-2. View

13.

Wernicke A, Dicker A, Whiton M, Ivanidze J, Hyslop T, Hammond E . Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. Radiat Oncol. 2010; 5:46. PMC: 2890616. DOI: 10.1186/1748-717X-5-46. View

14.

Sadetzki S, Flint-Richter P, Starinsky S, Novikov I, Lerman Y, Goldman B . Genotyping of patients with sporadic and radiation-associated meningiomas. Cancer Epidemiol Biomarkers Prev. 2005; 14(4):969-76. DOI: 10.1158/1055-9965.EPI-04-0366. View

15.

Guo D, Holmlund C, Henriksson R, Hedman H . The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics. 2004; 84(1):157-65. DOI: 10.1016/j.ygeno.2004.01.013. View

16.

Malmer B, Henriksson R, Gronberg H . Familial brain tumours-genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients. Int J Cancer. 2003; 106(2):260-3. DOI: 10.1002/ijc.11213. View

17.

Thomasson M, Wang B, Hammarsten P, Dahlman A, Persson J, Josefsson A . LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer. Int J Cancer. 2010; 128(12):2843-52. DOI: 10.1002/ijc.25820. View

18.

Sadetzki S, Flint-Richter P, Ben-Tal T, Nass D . Radiation-induced meningioma: a descriptive study of 253 cases. J Neurosurg. 2002; 97(5):1078-82. DOI: 10.3171/jns.2002.97.5.1078. View

19.

Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, Henriksson R . Characterization and tissue-specific expression of human LRIG2. Gene. 2004; 332:35-43. DOI: 10.1016/j.gene.2004.02.002. View

20.

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View